Bicycle Therapeutics plc (BCYC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bicycle Therapeutics (BCYC) PT Raised to $32 at Leerink Partners
October 31, 2024 1:10 PM EDTLeerink Partners analyst Jonathan Chang raised the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $32.00 (from $30.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: BCYC reported 3Q24 financial results and provided a pipeline update in line with expectations. BCYC highlighted continued pipeline progress across the portfolio, including the Bicycle Toxin Conjugate (BTC) and Bicycle Radio Conjugate... More
